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This report presents the activities implemented by the EMCDDA and Europol in 2010 in support of 
Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new 
psychoactive substances (hereinafter referred to as the Decision) (1).  
 
During 2010, 41 new psychoactive substances were officially notified for the first time in the 
European Union through the information exchange mechanism, the Early-Warning System (EWS), 
which was set up by the Decision. The number of new compounds reported in 2010 was higher 
than ever; the list of newly notified substances was rather diverse and included a plant-based 
substance, synthetic derivatives of well-established drugs, as well as substances that can be 
described as ‘designer medicines’. Under the so-called ‘Spice’ phenomenon, 11 new synthetic 
cannabinoids were reported, bringing the total number of synthetic cannabinoids monitored by the 
EWS to 21. The report also highlights the emergence of 15 new synthetic cathinone derivatives 
and notes the appearance for the first time of derivatives of phencyclidine (PCP) and ketamine.  
 
Furthermore, the report describes the increased availability of a large number of new unregulated 
synthetic compounds marketed on the Internet as ‘legal highs’ (2) as well as the EMCDDA’s 
activities in monitoring the online shops selling these products.  
 
In January 2010, after examining the available information collected on mephedrone (4-
methylmethcathinone), the EMCDDA and Europol decided to launch a procedure for the 
production of a joint report. Pursuant to the findings of this report, the Council of the EU formally 
requested a risk assessment of the substance. The risk assessment exercise was undertaken on 
15 July by the EMCDDA Scientific Committee, with the participation of additional experts from the 
EU Member States, the European Commission, Europol and the European Medicines Agency 
(EMA). Based on the findings of the risk assessment report, on 2 December 2010, the Council 
decided to submit mephedrone to control measures and criminal penalties throughout the 
European Union.  
 
Finally, the last two sections include a brief review of the key developments in the period 2005–10 
and a look at some of the challenges for the coming years. In particular, the focus is on issues that 
relate to the challenges for identifying, monitoring and assessing the risks of various new 
substances, which increasingly appear on the Internet and on the European drug markets.  
 
In view of the ongoing assessment of the Council Decision 2005/387/JHA undertaken by the 
European Commission in the framework of the EU drugs action plan for 2009–12 (3), this report 
may provide additional insight into the functioning of the Decision. 
 
                                                 
(1) OJ L 127, 20.5.2005, p. 32.  
(2)  ‘Legal highs’ is an umbrella term for internationally unregulated psychoactive compounds or products containing them, 
specifically designed to mimic the effects of known (established) drugs in order to circumvent existing drug controls. The term 
encompasses a wide range of synthetic and plant-derived substances and products, including ‘research chemicals’, ‘party 
pills’, ‘herbal highs’, etc., which are usually sold via the Internet or in smart/head shops, advertised with aggressive and 
sophisticated marketing strategies, and in some cases intentionally mislabelled with purported ingredients differing from the 
actual composition. The ‘legal highs’ market is distinguished by the speed at which suppliers circumvent drug controls by 
offering new alternatives to restricted products. 
(3) EU drugs action plan for 2009–2012, (2008/C 326/09) [Official Journal of the European Union C 326/7 IV, 20.12.2008]. 
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1. Introduction and background 
The Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk 
assessment and control of new psychoactive substances establishes a mechanism for the rapid 
exchange of information on new psychoactive substances that may pose public health and social 
threats, including the involvement of organised crime. This allows European Union institutions and 
Member States to act on all new narcotic and psychotropic substances that appear on the 
European Union drug scene (4). The Decision also provides for an assessment of the risks 
associated with these new substances, so that measures applicable in the Member States for the 
control of narcotic and psychotropic substances can also be applied to new psychoactive 
substances (5).  
 
The EMCDDA and Europol, in close collaboration with their networks, the Reitox National Focal 
Points (NFPs) and Europol National Units (ENUs) respectively — are assigned a central role in 
detecting and reporting new psychoactive substances (Article 4 of the Decision). Furthermore, in 
cooperation with the European Medicines Agency (EMA), the two organisations may collect, 
analyse and present information on a new psychoactive substance in the form of a joint report 
(Article 5). The joint report provides evidence-based advice to the Council and the Commission on 
the need to request a risk assessment on a new psychoactive substance. Such a risk assessment 
examines the health and social risks posed by the use of, manufacture of, and traffic in a new 
psychoactive substance, the involvement of organised crime and the possible consequences of 
control measures. In order to carry out the risk assessment, the EMCDDA convenes a special 
meeting under the auspices of its Scientific Committee (Article 6). 
 
To ensure transparency in the implementation of the Decision, Article 10 stipulates that: ‘The 
EMCDDA and Europol shall report annually to the European Parliament, the Council and the 
Commission on the implementation of this Decision. The report will take into account all aspects 
required for an assessment of the efficacy and achievements of the system created by this 
Decision. The report shall, in particular, include experience relating to coordination between the 
system set out in this Decision and the Pharmacovigilance system.’ 
 
In compliance with the above provision, the EMCDDA and Europol herein present the sixth Annual 
Report on the implementation of the Decision for the period January to December 2010. The report 
outlines the results of the implementation and describes key issues arising from accumulated 
experiences. Thus, the report also serves as a monitoring tool, which provides the Commission 
with information for the ongoing assessment of the functioning of Council Decision 2005/387/JHA 
included in the EU drugs action plan for 2009–12.  
 
The report is written as a stand-alone document with its annexes kept to a minimum. The report 
frequently refers to articles of the Decision; therefore, to facilitate its reading, the full text of the 
Decision is annexed (Annex 1). When describing the notified new psychoactive substances, the 
report presents sufficiently detailed information, while avoiding highly technical descriptions (the 
complete list of newly notified psychoactive substances, which includes detailed information on the 
chemical names, the reporting Member State, and date of notification is presented in Annex 2). 
More comprehensive information on the new substances described in the report is available from 
the EMCDDA and Europol.  
 
 
                                                 
(4)  Under the definitions of the Council Decision, ‘new psychoactive substance’ means a new narcotic drug or a new psychotropic 
drug in pure form or in a preparation; ‘new narcotic drug’ means a substance, in pure form or in a preparation, that has not 
been scheduled under the 1961 United Nations Single Convention on Narcotic Drugs, and that may pose a threat to public 
health comparable to the substances listed in Schedules I, II or IV; ‘new psychotropic drug’ means a substance in pure form 
or in a preparation that has not been scheduled under the 1971 United Nations Convention on Psychotropic Substances, and 
that may pose a threat to public health comparable to the substances listed in Schedules I, II, III or IV. 
(5) In compliance with the provisions of the 1961 UN Single Convention on Narcotic Drugs and the 1971 UN Convention on 
Psychotropic Substances. 
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2. Implementation arrangements and cooperation with the EU Pharmacovigilance system 
2.1 Specific implementation arrangements 
2.1.1 Implementation of the new Operating guidelines for the risk assessment  
The new Operating guidelines for the risk assessment of new psychoactive substances (6), 
elaborated by the EMCDDA’s Scientific Committee, were published in 2010. The guidelines, which 
were implemented for the first time for the risk assessment of mephedrone (see Section 3.2), are 
not only a useful tool to support the implementation of the Council Decision, but also provide an 
overall conceptual framework for conducting scientifically sound risk assessment in a timely 
fashion and where information sources are limited.  
2.1.2 Cooperation with the United Nations system 
Article 5.2(e) of the Decision requires the Europol–EMCDDA joint report to include information on 
‘whether or not a new substance is currently under assessment, or has been under assessment by 
the UN system’. In compliance with the above, information was requested from the World Health 
Organization (WHO) (7) on the assessment status of mephedrone in the UN system (see Section 
3.2). The WHO informed the EMCDDA that mephedrone was not under assessment in the UN 
system. 
2.1.3 Assistance to national EWSs  
The European EWS regularly provides support to partners from the national EWSs assisting them 
in the identification of new substances. This is done by providing analytical data, exchanging data 
between forensic laboratories, cross-checking information from the national databases and 
facilitating the exchange of drug samples where this is possible. Such activities prove to be useful 
for the identification of new psychoactive substances in the absence of reference materials, or 
where limited resources are available at national level. Moreover, the EMCDDA coordinates the 
information exchange related to relevant national projects. For example, some Member States 
have launched specific activities to monitor new drugs through test-purchases from the Internet 
and from specialised shops (smart, head, etc.). As a result, a significant number of new 
substances have been identified in ‘legal high’ products. 
 
The EWS is frequently consulted by the Member States, individual experts, scientists and, 
increasingly, the media (8) in relation to various new psychoactive substances. The EMCDDA is 
currently coordinating the preparation of a publication on national early-warning systems, with the 
objective of presenting a comprehensive overview of these systems. The publication, which is due 
in 2011, will promote best practices and enhance the exchange of experiences.  
2.1.4 Structured monitoring of the Internet — online availability of ‘legal highs’  
Leading-edge indicators such as monitoring the online availability of new psychoactive substances 
can be considered particularly sensitive to change. However, this sensitivity, by definition, is 
associated with volatility. As such, leading-edge indicators may be unreliable in the medium term if 
viewed in isolation and not triangulated with other data sources. Therefore, to complement the 
main EWS data sources such as seizures, reports on use and toxicity, the EMCDDA actively 
monitors the online availability of unregulated psychoactive products (‘legal highs’). One of the 
                                                 
(6) EMCDDA, 2010. Operating guidelines for risk assessment of new psychoactive substances. Also available at: 
http://www.emcdda.europa.eu/html.cfm/index100978EN.html 
(7) The World Health Organization (WHO) is the specialised United Nations Agency designated for the evaluation of medical, 
scientific and public health aspects of psychoactive substances under the 1961 and 1971 United Nations drug control 
conventions.  
(8) More than 50 television, radio and press interviews were given in 2010 to major European media, as follows: TVI, BBC, The 
Guardian, The Daily Telegraph, The Wall Street Journal, Wales online, Irish Sunday Mirror, Irish Independent, EU Observer, 
Diário de Notícias (Portugal), Público (Spain), Público (Portugal), El Mundo, El País, Metro France, Metroxpress and 24timer, 
Antena 1 (Portugal), Radio TSF, A2prl, Europe 1, etc.) on issues related to new drugs, ‘legal highs’, mephedrone, etc.  
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main potentials for the EMCDDA to be of added value in this area resides in the multilingual 
approach to this global phenomenon and the utilisation of sound methodology over time.  
 
In 2010, an EMCDDA steering group for Internet monitoring was set up to define the scope and to 
develop a conceptual framework and methodology for structured Internet monitoring. A paper on 
‘EMCDDA Internet monitoring methodology and results’ was prepared and will be published in 
2011 as an EMCDDA Technical paper.  
Internet monitoring is carried out in the form of snapshots, which are performed during a short time 
window on one or more substances and/or products. The EMCDDA has undertaken a number of 
snapshots relating to the availability of different kinds of new psychoactive substances. Earlier 
EMCDDA snapshot exercises focused on magic mushrooms in 2006 (9) and GHB/GBL in 2007 (10). 
In 2008, the scope was widened to ‘legal highs’ and in 2009 a snapshot was carried out on ‘Spice’ 
(11). The 2010 annual snapshot was multilingual and its objective was to establish the online 
availability of ‘legal highs’ (including ‘Spice’), GHB/GBL or hallucinogenic mushrooms. Additional 
EMCDDA snapshots were carried out in 2010, some of which focused on mephedrone as well as 
other substances of interest such as naphyrone, MDAI, etc.  
The 2011 annual snapshot (in 15 EU languages) was wider in scope (including mephedrone) and 
preliminary results suggest a considerable increase since 2010 in the online availability of ‘legal 
highs’, GBL or hallucinogenic mushrooms. The total number of online drugs shops offering at least 
one of the substances/products mentioned rose from 170 to 277. The increase was found to be 
mostly of generic sites selling ‘legal highs’ (often named as ‘herbal highs’ or ‘research chemicals’). 
With regards to a specific substance such as GBL, the 2010 snapshot found four online shops 
offering it, whereas twelve such shops were identified in the 2011.  
There were also examples of products, such as ‘Spice’, for which online availability decreased. In 
the 2011 snapshot, the number of online shops offering ‘Spice’ (under this generic name, e.g. 
Spice Gold/Diamond/Silver/Arctic/Tropical, etc.) dropped to four. This was down from the 21 and 
55 such shops identified in 2010 and 2009 respectively.  
Ad hoc snapshots for mephedrone in English showed a peak in March 2010 with 77 online shops 
offering it. The number of online mephedrone shops then decreased to seven in July 2010, but has 
risen since then to fifteen in February 2011. Similarly, an increasing availability of mephedrone 
through online shops seemingly located in Central Europe has been observed from 2010 to 2011.  
2.2 Cooperation with the EMA and the Pharmacovigilance system 
The European Medicines Agency (EMA) is a key partner in the implementation of the system set 
up by the Decision. The EMCDDA and EMA have established a mechanism for bilateral exchange 
of information on the basis of data available through the Early-Warning System and the European 
Union Pharmacovigilance system. Electronic tools such as the existing databases — 
EudraVigilance (EMA) and the European Database on New Drugs (EDND, EMCDDA) are being 
used to allow a rapid and reliable exchange of information. The regular information exchange 
between the EMCDDA and EMA includes formal reports on new psychoactive substances through 
a Reporting Form, as well as ad hoc reports on misused medicinal products in order to 
complement the reporting via the EU Pharmacovigilance system. In 2010, a Working arrangement 
was signed between the two Agencies in order to enhance further the cooperation while avoiding 
duplication of efforts and overlaps and to ensure the best use of available resources.  
 
In 2010, in accordance with Article 5.3 of the Decision, the EMA was requested to submit to the 
EMCDDA information on ‘whether in the European Union or in any Member State: (a) mephedrone 
                                                 
(9) EMCDDA, 2006. Hallucinogenic mushrooms. Thematic papers, European Monitoring Centre for Drugs and Drug Addiction. 
Available at: http://www.emcdda.europa.eu/html.cfm/index31208EN.html 
(10) EMCDDA, 2008. GHB and its precursor GBL: an emerging trend case study. Thematic papers, European Monitoring Centre 
for Drugs and Drug Addiction. Available at: http://www.emcdda.europa.eu/publications/thematic-papers/ghb 
(11) EMCDDA, 2009. Understanding the 'Spice' phenomenon, Thematic papers, European Monitoring Centre for Drugs and Drug 
Addiction. Available at: http://www.emcdda.europa.eu/publications/thematic-papers/spice 
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had obtained a marketing authorisation; (b) mephedrone was the subject of an application for a 
marketing authorisation; (c) a marketing authorisation that had been granted in respect to 
mephedrone had been suspended’ (see Section 3.2). The EMA collected information through its 
network of competent authorities for medicinal products and informed that mephedrone has no 
known medical use (human or veterinary) in the European Union and that there is no marketing 
authorisation (existing, ongoing or suspended) for mephedrone in the EU or in the Member States 
that responded to the EMA. 
 
During the reporting period, consultations and exchange of information took place on pregabalin — 
a prescription medicine marketed under the name Lyrica and used to treat neuropathic pain, 
epilepsy and generalised anxiety disorder (GAD). User reports suggest that pregabalin is used in 
recreational settings, with effects similar to those of alcohol, GHB (gamma-hydroxybutyric acid) 
and benzodiazepines. It is also reported to alleviate heroin (opioid) withdrawal symptoms.  
 
As reported in last year’s report, a review of pharmacovigilance data indicated concerns related to 
its misuse in Finland, Sweden and Norway. Furthermore, information from the EWS indicated that 
pregabalin may have been involved in the deaths of a number of users in Finland and the United 
Kingdom, where it was found in forensic toxicological analyses.  
 
Based on the information provided, the EMA felt that a specific warning should be given in the 
section Special warnings and precautions of the Summary of Product Characteristics (SPC) of 
Lyrica. The Pharmacovigilance Working Group (PhVWG) is expecting the results of a study (12) 
which will be submitted in January 2012. The objective of the study is to provide general long-term 
efficacy and safety information on Lyrica in the treatment of patients with GAD and to characterise 
the effects of pregabalin dose and treatment duration on drug discontinuation symptoms and 
rebound anxiety. 
 
Finally, in 2010 the EMCDDA launched a study to conceptualise a methodology for monitoring the 
misuse of medicines at European level. The results of the study will be available at the beginning 
of 2011. 
                                                 
(12) GAD Study A0081147.  
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3. Results achieved in 2010  
3.1 New psychoactive substances notified in 2010 
During 2010, a total of 41 new psychoactive substances were officially notified for the first time in 
European Union via the EWS (cp. Annex 2). This is the largest number of substances ever 
reported in a single year. The marked increase in the number of substances notified takes place in 
the context of the rapid development of the ‘legal highs’ phenomenon and may reflect both, the 
number of substances available in the EU as well as the improved reporting capacities of national 
early-warning systems due to the increased awareness about new drugs amongst various 
professionals. Many of the newly identified substances have been actively sought through test-
purchases of ‘legal highs’ products on the Internet and from specialised (smart, head, etc.) shops 
(see also Section 2.1.3). 
 
Of the newly identified substances, 15 were synthetic cathinones (13,14) thus becoming one of the 
largest drug families monitored by the EWS. Furthermore, 11 new synthetic cannabinoids (15,16) 
were reported (these are dealt separately in Section 3.3). Substances belonging to more 
‘traditional’ chemical families were also reported — five phenethylamines (17), one tryptamine (cp. 
Annex 2, substance 26) and one piperazine (cp. Annex 2, substance 1).  
 
The list of newly notified substances was rather diverse and also included a plant-based substance 
(cp. Annex 2, substance 37), a synthetic cocaine derivative (cp. Annex 2, substance 12) (18), a 
ketamine derivative (cp. Annex 2, substance 32), a phencyclidine derivative (Annex 2, substance 
35), an aminoindane (cp. Annex 2, substance 2), a benzofuran (cp. Annex 2, substance 40), a 
simple aliphatic amine (cp. Annex 2, substance 11), as well as a substance which can be 
described as a ‘designer medicine’ (cp. Annex 2, substance 41).  
 
From the above list, it is worth noting the appearance for the first time of derivatives of two well-
established drugs: phencyclidine (PCP) — an internationally controlled substance, and ketamine 
— a human and veterinary medicine. It can be anticipated that further derivatives of these drugs 
may appear in future.  
 
Following the formal notifications received through a Reporting Form, 41 new profiles for the new 
substances were created in the European Database on New Drugs (EDND). In addition, EMCDDA 
implements a longer-term monitoring through biannual EWS reports. Based on the information 
collected and analysed, the list of all notified substances is reviewed regularly by the EMCDDA and 
Europol in order to identify those with a potential to trigger a joint report.  
3.2 Risk assessment of mephedrone  
At the end of 2009 and in January 2010, the EMCDDA and Europol examined the available 
information on mephedrone, through a joint assessment based upon the criteria set out in the EWS 
operating guidelines (19). The Agencies agreed that the information available on mephedrone 
satisfied all criteria. Therefore, the two organisations concluded that sufficient evidence had been 
                                                 
(13)  Annex 2, substances 9, 10, 14, 15, 18, 20, 21, 23, 24, 27, 29, 34, 36, 38, 39. 
(14)  EMCDDA Drug profile (2010), Synthetic cathinones. Also available at: http://www.emcdda.europa.eu/publications/drug-
profiles/synthetic-cathinones 
(15)  Annex 2, substances 7, 8, 13, 16, 17, 19, 22, 28, 30, 31, 33. 
(16) EMCDDA Drug profile (2009), Synthetic cannabinoids and 'Spice'. Also available at: 
http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids 
(17)  Annex 2, substances 3, 4, 5, 6, 25. 
(18)  EMCDDA Drug profile (2010), Synthetic cocaine derivatives. Also available at: 
http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cocaine-derivatives  
(19) EMCDDA, 2007. Early-warning system on new psychoactive substances – operating guidelines. Also available at: 
http://www.emcdda.europa.eu/themes/new-drugs/early-warning 
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gathered and decided to launch a formal procedure for the collection of information for the 
production of a joint report (20).  
 
In view of the above, the Reitox NFPs and the ENUs provided the information as requested by 
Article 5 of the Decision within six weeks from the date of the request. On 29 March 2010, the 
Europol–EMCDDA joint report on the new psychoactive substance 4-methylmethcathinone 
(mephedrone) with its annexes was submitted to the Council, the Commission and the EMA (21). 
Consequently, on 26 May 2010 the Council upon an initiative from the Commission decided to 
authorise a formal risk assessment on mephedrone (Article 6).  
 
The risk assessment exercise on mephedrone was prepared by the EMCDDA and all available 
information was presented in three separate reports (‘Technical report on mephedrone’, 
‘Mephedrone: assessment of health risks and harms’, and ‘Mephedrone: additional studies —
Overview of prevalence, use patterns, effects)’. The risk assessment meeting of the EMCDDA’s 
extended Scientific Committee (22) was organised on 15 July, resulting in a Risk assessment report 
on mephedrone, which was submitted to the Commission and the Council (23).  
 
On the basis of the Risk assessment report, on 2 December 2010 the Council, upon an initiative of 
the Commission, decided to submit mephedrone to control measures and criminal penalties 
throughout the EU according to Article 8 (3) of the Decision. These measures entered into force on 
9 December 2010. By that time, sixteen Member States had already introduced control measures 
on mephedrone (24). The remaining Member States (25) have one year to take the necessary 
measures, in accordance with their national law (Article 9).  
 
Mephedrone is the first cathinone derivative to be risk-assessed by the extended Scientific 
Committee of the EMCDDA, as part of the process established by Council Decision 2005/387/JHA. 
This risk assessment built on the lessons learnt during previous exercises, in particular the risk 
assessment of BZP (2007) (26), but also introduced a new methodological approach through the 
implementation, for the first time, of the new EMCDDA Operating guidelines for risk assessment of 
new psychoactive substances (cp. Section 2.1.1). 
 
The risk assessment on mephedrone was particularly difficult, due not only to limited data available 
on this substance, but also to the fact that there was very little similarity to other compounds which 
have been previously risk-assessed through the Council Decision mechanism. It is worth noting 
that for this risk assessment, the EMCDDA made it possible to conduct a toxicological screening in 
the framework of an exploratory study, which examined the patterns of use and adverse effects of 
mephedrone amongst a group of self-reported cathinone users. This study presented the Scientific 
Committee with important additional information, thus greatly facilitating the work and allowing the 
findings to be better grounded in evidence.  
 
                                                 
(20) Article 5.1 of the Decision stipulates that ‘Where Europol and the EMCDDA, or the Council, acting by a majority of its 
members, consider that the information provided by the Member State on a new psychoactive substance merits the collection 
of further information, this information shall be collated and presented by Europol and the EMCDDA in the form of a Joint 
Report.'  
(21) EMCDDA, 2010. Europol–EMCDDA Joint Report on a new psychoactive substance: 4-methylmethcathinone (mephedrone). 
Also available at: http://www.emcdda.europa.eu/themes/new-drugs/early-warning   
(22) The EMCDDA's extended Scientific Committee included the participation of additional experts from the EU Member States, 
European Commission, Europol and the European Medicines Agency (EMA). 
(23) EMCDDA, 2010. Risk assessment report of a new psychoactive substance: 4-methylmethcathinone (mephedrone). Also 
available at: http://www.emcdda.europa.eu/html.cfm/index116639EN.html   
(24)  Austria, Belgium, Denmark, Estonia, France, Germany, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Poland, Romania, 
Sweden, the United Kingdom, as well as Croatia and Norway.  
(25) At the time of writing this report, control measures had also been introduced by Bulgaria, Greece, Hungary and Spain, and 
there were indications that several other countries were considering them.  
(26) EMCDDA, 2009. Report on the risk assessment of BZP in the framework of the Council decision on new psychoactive 
substances. Also available at: http://www.emcdda.europa.eu/publications/risk-assessments/bzp 
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Concluding the risk assessment report, the Scientific Committee noted that a decision to control 
this drug has the potential to bring with it both positive and negative consequences. Potential 
positive consequences may include reduced availability and use of the drug. It is important, 
however, to anticipate and minimise any potential negative consequences of control. Control 
measures could create an illegal market in mephedrone with the associated risk of criminal activity. 
Furthermore, control should not inhibit the gathering and dissemination of accurate information on 
mephedrone to users and to relevant professionals.  
3.3 ‘Spice’ and synthetic cannabinoids  
Since 2008, the ‘Spice’ phenomenon and the related psychoactive constituents, synthetic 
cannabinoid receptor agonists, have received considerable attention. In 2010, 11 new synthetic 
cannabinoids were reported via the EWS, bringing a total number of synthetic cannabinoids 
reported to more than 20. The compounds reported so far belong to six different chemical groups: 
naphthoylindoles (most of the JWH-compounds), phenylacetylindoles (JWH-250 and JWH-203), 
cyclohexylphenols (CP-compounds), classical cannabinoids (HU-210); and the two newly reported 
families in 2010 — benzoylindoles (27) and naphthoylnaphthalenes (28). These substances, often 
encountered in various combinations, are difficult to identify analytically and clearly pose 
challenges to forensic scientists.  
 
The extent to which these products are used is largely unknown. A number of surveys aiming at 
examining the prevalence of use of ‘Spice’-like products have been launched but the coverage and 
representativeness of the studies carried out are very limited. 
 
Neither the purported herbal ingredients of ‘Spice’ and ‘Spice’-like products, nor any of the 
synthetic cannabinoids found in them are internationally controlled under the 1961 or 1971 United 
Nations drug control conventions. 
 
Responding to potential health concerns, at least 16 European countries have taken legal actions 
to ban or otherwise control ‘Spice’ products and related compounds as follows (in chronological 
order): Austria (January 2009), Germany (January 2009, emergency regulation; January 2010 
permanent control), France (February 2009), Luxembourg (generic/analogue approach, May 
2009), Poland (May 2009), Lithuania (May 2009), Estonia (July 2009), Sweden (September 2009), 
Latvia (November 2009), the United Kingdom (generic approach, December 2009), Romania 
(February 2010), Denmark (March 2010), Ireland (generic approach, May 2010), Italy (June 2010), 
Turkey (January 2011) and Bulgaria (February 2011).  
 
Some Member States have placed one or more of the claimed herbal ingredients of ‘Spice’, such 
as Leonotis leonurus and Nymphaea caerulea (Poland and Latvia control both and Romania only 
the latter), on their lists of controlled substances. From May 2009, Switzerland controls ‘Spice 
herbal mixes’ under food regulation (5 grams allowed for personal use). Furthermore, in Belgium, 
synthetic cannabinoids are included in doping control measures. 
 
Health-related adverse effects have been associated to ‘Spice’-like products. At the end of 2010, 
Italy reported a number of hospitalisations due to adverse effects allegedly associated to JWH-122, 
found in 'Forest green' and 'Jungle Mistic Incense' products. In addition, Germany reported 
adverse effects attributed to the 'Lava red' product, which also contained JWH-122. This synthetic 
cannabinoid, which is a highly potent agonist at the CB1 receptor, is monitored closely by the EWS. 
It was first notified in July 2010 and since then it has been encountered in at least eleven Member 
States, and in considerable amounts.  
3.4 Public health warnings  
The Council Decision stimulates the identification, monitoring and exchange of information on 
emerging trends in new uses of existing substances and on possible public health-related 
                                                 
(27) RCS-4, 3-(4-hydroxymethylbenzoyl)-1-pentylindole, and AM-694.  
(28) CRA-13, notified in January 2011.  
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measures. The warning on adverse health effects of new psychoactive substances through timely 
and rapid public health alerts is one of the core activities of the EMCDDA EWS. In addition, in 
2010, the EWS issued public health warnings to the Reitox network concerning unusual hazards of 
occurrences related to controlled drugs.  
3.4.1 Adverse health effects related to new drugs 
In 2010, the EWS issued public health warnings concerning adverse health effects of the following 
new psychoactive substances: 
 
- MDPV  
MDPV (29), first reported in 2008 by the United Kingdom and by Finland, is a derivative of 
pyrovalerone, which is controlled under Schedule IV of the 1971 UN Convention. Some fatalities 
and adverse health effects associated to the use of MDPV were reported in Finland and in the UK.  
 
- Fluorotropacocaine (pFBT) 
Fluorotropacocaine (first reported in 2008 by Finland) is a tropane derivative drug, which acts as a 
stimulant and local anaesthetic. Adverse effects associated to fluorotropacocaine were reported by 
Ireland in June 2010, where the substance was identified in two head shop products. The 
symptoms included increased heart rate, increased breathing rates and raised blood pressure. The 
majority of the patients experienced differing levels of anxiety and at least seven cases of 
psychotic episodes.  
 
- Para-methoxyamphetamine (PMA) and para-methoxymethylamphetamine (PMMA) 
Both PMA (30) and PMMA are known to have considerable toxicity and to have been responsible 
for fatal overdoses in the past. PMMA was risk assessed in 2001 in the framework of the 1997 
Joint action on new synthetic drugs (31) and consequently controlled at European level.  
 
In October 2010, the Dutch Drug Information Monitoring System (DIMS) alerted about their findings 
of powders sold as amphetamine, which contained up to 5–10% PMA and tablets with high content 
of PMMA sold as ecstasy. In the meantime it became clear that in Norway and in the Netherlands 
there had been a number of health incidents and fatalities related to PMMA, and a considerable 
number of PMMA seizures in Norway. 
  
- Desoxypipradol (2-DPMP) 
Desoxypipradrol (first reported in 2009 by Finland) is a close relative of pipradrol, which is listed in 
Schedule IV of the UN 1971 Convention. In October 2010, the United Kingdom NFP reported three 
fatal cases associated to desoxypipradol, one of which was related to the consumption of a sample 
of ‘Ivory Wave’, which contained the substance. 
 
- 2-(Diphenylmethyl)pyrrolidine (desoxy-D2PM) 
This stimulant substance, which is structurally related to diphenylprolinol (D2PM) and 
desoxypipradrol (which is in turn a derivative of pipradrol), has been reported in body-building 
products and is commercially available. In the United Kingdom, adverse health effects including 
severe and prolonged psychosis, raised heart rate and blood pressure were associated to the 
product ‘A3A Methano’, which contained desoxy-D2PM.  
3.4.2 Unusual hazards of occurrences related to controlled drugs 
In December 2009, an outbreak of anthrax among heroin injecting drug users was reported in 
Scotland, followed by additional fatalities in Germany and England. The European Centre for 
Disease Prevention and Control (ECDC) and the EMCDDA conducted a Joint threat assessment 
                                                 
(29) MDPV (3,4-Methylenedioxypyrovalerone) is a cathinone.  
(30)  Listed in Schedule I of the 1971 UN Convention on Psychotropic Substances since 1986. 
(31)  EMCDDA, 2003. Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs. Also 
available at: http://www.emcdda.europa.eu/html.cfm/index33349EN.html 
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(32) and the EWS also issued an alert to the Reitox NFPs. In 2010, a follow up of the outbreak 
revealed additional related fatalities in the United Kingdom and Germany.  
 
In June 2010, the UK Health Protection Agency issued an alert on the risks of wound botulism 
among injecting heroin users, after a case reported in London. Wound botulism is caused by 
botulinum toxin that is commonly found as spores in soil, and the source of the infection in the 
reported case was likely due to a batch of heroin contaminated with the bacteria. Following this 
alert, another case was reported in Germany. 
 
In November 2010, information from the media about heroin shortage in the United Kingdom and 
Ireland prompted the EWS to issue an alert and to launch a revealing information collection on 
national situations. The results showed that while in some countries there seemed to be no 
evidence of such shortage (Romania, Portugal, France), the information received from Bulgaria, 
Poland, Slovenia, Switzerland, and Malta supported that information. 
 
In Switzerland, several intoxications and fatalities among habitual cocaine users occurred due to 
unsuspected consumption of heroin. An alert was sent to the EWS of the neighbouring countries in 
January 2010, which allowed the identification of similar cases in Italy. In September 2010, a case 
of white heroin sold as cocaine was reported also in Switzerland, where the samples had been cut 
with more than 60 % of phenacetin, an adulterant typically used for cocaine. Following this alert, 
some Member States provided composition analysis of adulterated heroin samples. 
                                                 
(32) Joint ECDC–EMCDDA threat assessment of the anthrax outbreak among heroin injecting drug users in Scotland and 
Germany (2009).  
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4. Key developments in the period 2005–10 
The new drugs phenomenon has been going through a period of dynamic change during the last 
few years. The appearance of a large number of new unregulated synthetic compounds marketed 
on the Internet as ‘legal highs’ or ‘not for human consumption’ and specifically designed to 
circumvent drug controls shows the speed and sophistication at which the market reacts to control 
measures, and how globalisation and innovation present a growing challenge to current 
approaches to new psychoactive substances. This is illustrated not only in the increased number, 
but also in the diversity in type, of substances that have appeared on the European market. The 
spring and diversity of new drug families is largely due to the increased complexity and volatility of 
the European drugs market and to the way that these substances are being produced, distributed 
and marketed.  
 
To ‘design’ a drug to replace a controlled substance is not a new concept. In the past, though, 
designer drugs were illicitly produced and marketed directly on the illicit market (from those based 
on fentanyl in the 1980s, to ring-substituted phenethylamines in the late 1980s and tryptamines in 
1990s; to piperazines and cathinone derivatives in the early 2000s). An important difference today 
is the new interaction between the illicit and non-illicit markets, where chemicals are legally 
sourced but then sold as replacements for illicit psychoactive substances. In this context, it is 
important to consider the threat posed by the undesirable transition from a mostly online ‘legal 
highs’ market, originally driven by individual entrepreneurship, to one that involves organised 
crime.  
 
The vast majority of the substances notified after the Council Decision 2005/387/JHA came into 
effect, i.e. after 21 May 2005, were new psychotropic substances (i.e. synthetic drugs) similar to 
those listed in Schedules I and II of the 1971 UN Convention on Psychotropic Substances. It 
seems likely that synthetic psychoactive substances will continue to play a major role and will be 
predominantly notified through the EWS. With rapid technological advances, for example, cheap 
organic synthesis coupled with the increased use of the Internet for marketing and selling new 
drugs, it may be expected that synthetic analogues of various drug groups will continue to appear. 
In the context of the ‘legal highs’ phenomenon it can be anticipated that the concept of new drugs 
will continue to evolve at an unprecedented speed. The appearance of synthetic cannabinoids, 
synthetic cocaine derivatives, ketamine and phencyclidine derivatives mark the latest stages in this 
development.  
 
In 2009–10, the EWS received reports of substances that were based on slight modifications of the 
chemical structures of medicines with known abuse potential. The rise of new ‘designer medicines’ 
would be an unwelcome addition to the task of ensuring that prescribed medicines are not diverted 
and misused. It is also another example of how innovation in the illicit market requires a robust and 
joined-up response from pharmaceutical and drug control regulatory frameworks. This issue is 
more of a potential threat than an immediate problem, but given the speed at which new 
developments occur in this area, it is important to anticipate future challenges. The suggestion that 
in the future we will see increasing numbers of new drugs based on existing pharmaceutical 
products but intended for non-therapeutic use would be particularly worrying.  
 
The discovery of a psychoactive substance outside legal control allows suppliers to make a profit, 
but at an unknown risk to the consumers’ health. One of the new developments of the ‘legal highs’ 
phenomenon is the rising and alarming potential health-related adverse effects associated to ‘legal 
highs’ products (see Section 3.3 and Section 3.4.1), and also the dynamic changes in the 
composition of the products. 
 
In the period 2005–10, three substances satisfied the criteria for the launch of a joint report.  From 
the information collected, Europol concluded that in each case organised crime was involved, even 
though this was often related to illicit tableting, distribution and sale of tablets with logo imprints 
usually associated with ecstasy (MDMA).  
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5. Outlook on future challenges 
5.1 Identification of new substances 
Over the last years, the number and diversity of new drugs are not only increasing rapidly but also 
becoming widespread. The flood of new substances requires substantial efforts to keep abreast of 
new developments. The effective recognition of substances presents not only analytical challenges 
but also requires the synergic cooperation of different laboratories (not only among different 
national services, but also internationally) and increased resources to provide for new-generation 
sophisticated analytical techniques. Owing to limited resources in forensic science laboratories, not 
all substances or components of all mixtures are necessarily identified, particularly those that at the 
time of analysis were not controlled. Furthermore, in the absence of reference standards, the 
complexity of some analytes causes further difficulties, particularly when mixtures or difficult 
matrices are present or when isomers may exist. The analysis of metabolites in body fluids also 
presents additional challenges. 
 
Among the initiatives to keep pace with new developments are projects on national test-purchase 
and analysis of the content of 'legal highs' products, which provide a snapshot of what is available 
on the EU market during a given (short) period of time and can contribute effectively to the 
dynamisation of drug monitoring systems. However, these projects, which are expensive and time 
consuming, are often based on the initiative of individual researchers, rather than on a structured 
European strategy.  
 
In this context, the availability of reference materials is of the utmost importance if forensic and 
toxicology laboratories are to identify new psychoactive substances, especially in the case of a 
new synthetic drug about which limited scientific literature is available. However, there is no 
European Union system for the synthesis and sharing of reference substances. If a system that 
can successfully function in the long term is to be implemented, it will be important to consider how 
coordination can be established and how access to reference materials can be facilitated as this is 
a key information challenge and an area in which coordinated actions bring clear added value. 
5.2 Risk assessment  
The need for more pre-risk assessment research (pharmacology, toxicology, epidemiology) as well 
as post-risk assessment monitoring (including research on impact of control measures) is 
increasingly recognised. However, as a response to some of the new developments, there have 
also been calls for a more ‘generic approach’ to assessing the risks (and consequently controlling) 
new substances. Although this kind of approach would be more cost-effective, it would also be 
more difficult practically and less scientifically robust, for example, there will be substantial 
variations in the effects, potential harms, etc., between the different substances included in any 
generic group. Furthermore, the size/composition of the group or class would be difficult to 




Recent developments have led to new psychoactive substances becoming widely available at an 
unprecedented pace. The speed at which they appear and the way they can be distributed 
challenges the established procedures for monitoring, responding to and controlling the use of new 
psychoactive substances. This is in turn reflected in much higher political, general public (media, 
society at large) and scientific interest and concern about the ‘legal highs’ phenomenon. 
 
Responding to the need to remain vigilant and react rapidly to new substances and products 
identified, the EWS network has increased its operational capacity and expanded to include not 
only new forensic science and toxicological laboratories, but also many independent researchers 
as well as a range of drug and law enforcement professionals. The use of quantitative routine 
epidemiological indicators, qualitative research and a wide range of multidisciplinary and 
supplementary information sources and leading-edge indicators (e.g. Internet monitoring) are 
increasingly combined in order to obtain a holistic picture of new trends at European level.  
 
All these have increased the profile of the EWS and the workload of the networks at national and 
European levels while resources often remain unchanged. A further observation of the current 
system is that it remains reactive rather than proactive. So whilst significant reporting capabilities 
now exist which facilitate the speedy exchange and triangulation of information from existing 
sources, the current system lacks the ability to anticipate emerging threats, by actively purchasing, 
synthesising, and studying new compounds. This deficiency could be addressed through 
investment to improve capacity for investigative forensic analysis and research at the European 
level, linked to the EWS. Both, the information exchange mechanism and the risk assessment 
would benefit if there was a clear mandate to purchase new psychoactive substances and analyse 
them; to purchase and synthesise reference samples; to disseminate analytical information to 






Annex 1: Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-
assessment and control of new psychoactive substances 
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(Acts adopted under Title VI of the Treaty on European Union)
COUNCIL DECISION 2005/387/JHA
of 10 May 2005
on the information exchange, risk-assessment and control of new psychoactive substances
THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty on European Union, and in
particular Articles 29, 31(1)(e) and 34 (2)(c) thereof,
Having regard to the proposal from the Commission,
Having regard to the opinion of the European Parliament (1),
Whereas:
(1) The particular dangers inherent in the development of
psychoactive substances require rapid action by the
Member States.
(2) When new psychoactive substances are not brought
within the scope of criminal law in all Member States,
problems may arise in cooperation between the judicial
authorities and law enforcement agencies of Member
States owing to the fact that the offence or offences in
question are not punishable under the laws of both the
requesting and the requested State.
(3) The European Union Action Plan on Drugs 2000-2004
provided for the Commission to organise an appropriate
assessment of the Joint Action of 16 June 1997
concerning the information exchange, risk assessment
and the control of new synthetic drugs (2) (herineafter
‘the Joint Action’) taking into account the external
evaluation commissioned by the European Monitoring
Centre on Drugs and Drug Addiction (hereinafter ‘the
EMCDDA’) of the early warning system. The assessment
showed that the Joint Action had fulfilled its expec-
tations. Nevertheless, the outcome of the assessment
made it clear that the Joint Action was in need of rein-
forcement and reorientation. In particular, its main
objective, the clarity of its procedures and definitions,
the transparency of its operation, and the relevance of
its scope had to be redefined. The Communication from
the Commission to the European Parliament and the
Council on the mid-term evaluation of the EU Action
Plan on Drugs (2000-2004) indicated that changes to
the legislation would be introduced in order to enhance
action against synthetic drugs. The mechanism as estab-
lished by the Joint Action should therefore be adapted.
(4) New psychoactive substances can be harmful to health.
(5) The new psychoactive substances covered by this
Decision may include medicinal products as defined in
Directive 2001/82/EC of the European Parliament and of
the Council of 6 November 2001 on the Community
Code relating to veterinary medicinal products (3) and
in Directive 2001/83/EC of the European Parliament
and of the Council of 6 November 2001 on the
Community Code relating to medicinal products for
human use (4).
(6) The information exchange under the early warning
system, established under the Joint Action, has proved
to be a valuable asset to the Member States.
(7) Nothing in this Decision should prevent Member States
from exchanging information, within the European Infor-
mation Network on Drugs and Drug Addiction (here-
inafter ‘the Reitox network’), on emerging trends in
new uses of existing psychoactive substances which
may pose a potential risk to public health, as well as
information on possible public health related measures,
in accordance with the mandate and procedures of the
EMCDDA.
(8) No deterioration of either human or veterinary health
care as a result of this Decision will be permitted.
Substances of established and acknowledged medical
value are therefore excluded from control measures
based on this Decision. Suitable regulatory and public
health related measures should be taken for substances
of established and acknowledged medical value that are
being misused.
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(1) Opinion delivered on 13 January 2004 (not yet published in the
Official Journal).
(2) OJ L 167, 25.6.1997, p. 1.
(3) OJ L 311, 28.11.2001, p. 1. Directive as last amended by Directive
2004/28/EC (OJ L 136, 30.4.2004, p. 58).
(4) OJ L 311, 28.11.2001, p. 67. Directive as last amended by Directive
2004/27/EC (OJ L 136, 30.4.2004, p. 34).
(9) In addition to what is provided for under the pharma-
covigilance systems as defined in Directive 2001/82/EC
and in Directive 2001/83/EC, the exchange of infor-
mation on abused or misused psychoactive substances
needs to be reinforced and appropriate cooperation
with the European Medicines Agency (hereinafter
‘EMEA’) ensured. The United Nations Commission on
Narcotic Drugs (hereinafter ‘CND’) Resolution 46/7
‘Measures to promote the exchange of information on
new patterns of drug use and on psychoactive substances
consumed’, provides a useful framework for action by the
Member States.
(10) The introduction of deadlines into every phase of the
procedure established by this Decision should guarantee
that the instrument can react swiftly and enhances its
ability to provide a quick-response mechanism.
(11) The Scientific Committee of the EMCDDA has a central
role in the assessment of the risks associated with a new
psychoactive substance, it will for the purpose of this
Decision be extended to include experts from the
Commission, Europol and the EMEA, and experts from
scientific fields not represented, or not sufficiently repre-
sented, in the Scientific Committee of the EMCDDA.
(12) The extended Scientific Committee that assesses the risks
associated with new psychoactive substances should
remain a concise technical body of experts, capable of
assessing effectively all risks associated with a new
psychoactive substance. Therefore the extended Scientific
Committee should be kept to a manageable size.
(13) Since the objectives of the proposed action, namely to
bring about an exchange of information, a risk-
assessment by a scientific committee and an EU-level
procedure for bringing notified substances under
control, cannot be sufficiently achieved by the Member
States and can therefore, by reason of the effects of the
envisaged action, be better achieved at European Union
level, the Union may adopt measures, in accordance with
the principle of subsidiarity as set out in Article 5 of the
Treaty. In accordance with the principle of propor-
tionality as set out in that Article, this Decision does
not go what is beyond what is necessary in order to
achieve those objectives
(14) In conformity with Article 34(2)(c) of the Treaty,
measures based upon this Decision can be taken by
qualified majority as these measures are necessary to
implement this Decision.
(15) This Decision respects fundamental rights and observes
the principles recognised by Article 6 of the Treaty and
reflected in the Charter of Fundamental Rights of the
European Union,
HAS DECIDED AS FOLLOWS:
Article 1
Subject matter
This Decision establishes a mechanism for a rapid exchange of
information on new psychoactive substances. It takes note of
information on suspected adverse reactions to be reported
under the pharmacovigilance system as established by Title IX
of Directive 2001/83/EC.
This Decision also provides for an assessment of the risks asso-
ciated with these new psychoactive substances in order to
permit the measures applicable in the Member States for
control of narcotic and psychotropic substances to be applied
also to new psychoactive substances.
Article 2
Scope
This Decision applies to substances not currently listed in any
of the schedules to:
(a) the 1961 United Nations Single Convention on Narcotic
Drugs, that may pose a comparable threat to public
health as the substances listed in Schedule I or II or IV
thereof, and
(b) the 1971 United Nations Convention on Psychotropic
Substances, that may pose a comparable threat to public
health as the substances listed in Schedule I or II or III or
IV thereof.
This Decision relates to end-products, as distinct from
precursors in respect of which Council Regulation (EEC) No
3677/90 of 13 December 1990 laying down measures to be
taken to discourage the diversion of certain substances to the
illicit manufacture of narcotic drugs and psychotropic
substances (1), and Regulation (EC) No 273/2004 of the
European Parliament and of the Council of 11 February 2004
on drug precursors (2) provide for a Community regime.
Article 3
Definitions
For the purpose of this Decision the following definitions shall
apply:
(a) ‘new psychoactive substance’ means a new narcotic drug or
a new psychotropic drug in pure form or in a preparation;
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(b) ‘new narcotic drug’ means a substance in pure form or in a
preparation, that has not been scheduled under the 1961
United Nations Single Convention on Narcotic Drugs, and
that may pose a threat to public health comparable to the
substances listed in Schedule I, II or IV;
(c) ‘new psychotropic drug’ means a substance in pure form or
in a preparation that has not been scheduled under the
1971 United Nations Convention on Psychotropic
Substances, and that may pose a threat to public health
comparable to the substances listed in Schedule I, II, III
or IV;
(d) ‘marketing authorisation’ means a permission to place a
medicinal product on the market, granted by the
competent authority of a Member State, as required by
Title III of Directive 2001/83/EC (in the case of medicinal
products for human use) or Title III of Directive
2001/82/EC (in the case of veterinary medicinal products)
or a marketing authorisation granted by the European
Commission under Article 3 of Regulation (EC)
No 726/2004 of the European Parliament and of the
Council of 31 March 2004 laying down Community
procedures for the authorisation and supervision of
medicinal products for human and veterinary use and estab-
lishing a European Medicines Agency (1);
(e) ‘United Nations system’ means the World Health Organi-
sation (WHO), the Commission on Narcotic Drugs (CND)
and/or the Economic and Social Committee acting in
accordance with their respective responsibilities as
described in Article 3 of the 1961 United Nations Single
Convention on Narcotic Drugs or in Article 2 of the 1971
United Nations Convention on Psychotropic Substances;
(f) ‘preparation’ means a mixture containing a new
psychoactive substance;
(g) ‘Reporting Form’ means a structured form for notification of
a new psychoactive substance and/or of a preparation
containing a new psychoactive substance agreed between
the EMCDDA/Europol and their respective networks in the
Member States’ Reitox and the Europol National Units.
Article 4
Exchange of information
1. Each Member State shall ensure that its Europol National
Unit and its representative in the Reitox network provide infor-
mation on the manufacture, traffic and use, including supple-
mentary information on possible medical use, of new
psychoactive substances and of preparations containing new
psychoactive substances, to Europol and the EMCDDA, taking
into account the respective mandates of these two bodies.
Europol and the EMCDDA shall collect the information received
from Member States through a Reporting Form and commu-
nicate this information immediately to each other and to the
Europol National Units and the representatives of the Reitox
network of the Member States, the Commission, and to the
EMEA.
2. Should Europol and the EMCDDA consider that the infor-
mation provided by a Member State on a new psychoactive
substance does not merit the communication of information
as described in paragraph 1, they shall inform the notifying
Member State immediately thereof. Europol and the EMCDDA
shall justify their decision to the Council within six weeks.
Article 5
Joint Report
1. Where Europol and the EMCDDA, or the Council, acting
by a majority of its members, consider that the information
provided by the Member State on a new psychoactive
substance merits the collection of further information, this
information shall be collated and presented by Europol and
the EMCDDA in the form of a Joint Report (hereinafter the
‘Joint Report’). The Joint Report shall be submitted to the
Council, the EMEA and the Commission.
2. The Joint Report shall contain:
(a) a chemical and physical description, including the name
under which the new psychoactive substance is known,
including, if available, the scientific name (International
Non-proprietary Name);
(b) information on the frequency, circumstances and/or quan-
tities in which a new psychoactive substance is encountered,
and information on the means and methods of manufacture
of the new psychoactive substance;
(c) information on the involvement of organised crime in the
manufacture or trafficking of the new psychoactive
substance;
(d) a first indication of the risks associated with the new
psychoactive substance, including the health and social
risks, and the characteristics of users;
(e) information on whether or not the new substance is
currently under assessment, or has been under assessment,
by the UN system;
(f) the date of notification on the Reporting Form of the new
psychoactive substance to the EMCDDA or to Europol;
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(g) information on whether or not the new psychoactive
substance is already subject to control measures at
national level in a Member State;
(h) as far as possible, information will be made available on:
(i) the chemical precursors that are known to have been
used for the manufacture of the substance,
(ii) the mode and scope of the established or expected use
of the new substance,
(iii) any other use of the new psychoactive substance and
the extent of such use, the risks associated with this use
of the new psychoactive substance, including the health
and social risks.
3. The EMEA shall submit to Europol and the EMCDDA the
following information on whether in the European Union or in
any Member State:
(a) the new psychoactive substance has obtained a marketing
authorisation;
(b) the new psychoactive substance is the subject of an appli-
cation for a marketing authorisation;
(c) a marketing authorisation that had been granted in respect
of the new psychoactive substance has been suspended.
Where this information relates to marketing authorisations
granted by Member States, these Member States shall provide
the EMEA with this information if so requested by it.
4. Member States shall provide the details referred to under
paragraph 2 within six weeks from the date of notification on
the Reporting Form as set out in Article 4(1).
5. The Joint Report shall be submitted no more than four
weeks after the date of receipt of the information from Member
States and the EMEA. The Report shall be submitted by Europol




1. The Council, taking into account the advice of Europol
and the EMCDDA, and acting by a majority of its members,
may request that the risks, including the health and social risks,
caused by the use of, the manufacture of, and traffic in, a new
psychoactive substance, the involvement of organised crime and
possible consequences of control measures, be assessed in
accordance with the procedure set out in paragraphs 2 to 4,
provided that at least a quarter of its members or the
Commission have informed the Council in writing that they
are in favour of such an assessment. The Member States or
the Commission shall inform the Council thereof as soon as
possible, but in any case within four weeks of receipt of the
Joint Report. The General Secretariat of the Council shall notify
this information to the EMCDDA without delay.
2. In order to carry out the assessment, the EMCDDA shall
convene a special meeting under the auspices of its Scientific
Committee. In addition, for the purpose of this meeting the
Scientific Committee may be extended by a further five
experts at most, to be designated by the Director of the
EMCDDA, acting on the advice of the Chairperson of the
Scientific Committee, chosen from a panel of experts
proposed by Member States and approved every three years
by the Management Board of the EMCDDA. Such experts will
be from scientific fields that are not represented, or not suffi-
ciently represented, in the Scientific Committee, but whose
contribution is necessary for the balanced and adequate
assessment of the possible risks, including health and social
risks. Furthermore, the Commission, Europol and the EMEA
shall each be invited to send a maximum of two experts.
3. The risk assessment shall be carried out on the basis of
information to be provided to the scientific Committee by the
Member States, the EMCDDA, Europol, the EMEA, taking into
account all factors which, according to the 1961 United Nations
Single Convention on Narcotic Drugs or the 1971 United
Nations Convention on Psychotropic Substances, would
warrant the placing of a substance under international control.
4. On completion of the risk assessment, a report (here-
inafter the ‘Risk Assessment Report’) shall be drawn up by
the Scientific Committee. The Risk Assessment Report shall
consist of an analysis of the scientific and law enforcement
information available, and shall reflect all opinions held by
the members of the Committee. The Risk Assessment Report
shall be submitted to the Commission and Council by the
chairperson of the Committee, on its behalf, within a period
of twelve weeks from the date of the notification by the General
Secretariat of the Council to the EMCDDA referred to in
paragraph 1.
The Risk Assessment Report shall include:
(a) the physical and chemical description of the new
psychoactive substance and its mechanisms of action,
including its medical value;
(b) the health risks associated with the new psychoactive
substance;
(c) the social risks associated with the new psychoactive
substance;
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(d) information on the level of involvement of organised crime
and information on seizures and/or detections by the autho-
rities, and the manufacture of the new psychoactive
substance;
(e) information on any assessment of the new psychoactive
substance in the United Nations system;
(f) where appropriate, a description of the control measures
that are applicable to the new psychoactive substance in
the Member States;
(g) options for control and the possible consequences of the
control measures, and
(h) the chemical precursors that are used for the manufacture of
the substance.
Article 7
Circumstances where no risk assessment is carried out
1. No risk assessment shall be carried out in the absence of a
Europol/EMCDDA Joint Report. Nor shall a risk assessment be
carried out where the new psychoactive substance concerned is
at an advanced stage of assessment within the United Nations
system, namely once the WHO expert committee on drug
dependence has published its critical review together with a
written recommendation, except where there is significant
new information that is relevant in the framework of this
Decision.
2. Where the new psychoactive substance has been assessed
within the United Nations system, but it has been decided not
to schedule the new psychoactive substance under the 1961
Single Convention on Narcotic Drugs or the 1971 Convention
on Psychotropic Substances, a risk assessment shall be carried
out only if there is significant new information that is relevant
in the framework of this Decision.
3. No risk assessment shall be carried out on a new
psychoactive substance if:
(a) the new psychoactive substance is used to manufacture a
medicinal product which has been granted a marketing
authorisation; or,
(b) the new psychoactive substance is used to manufacture a
medicinal product for which an application has been made
for a marketing authorisation or,
(c) the new psychoactive substance is used to manufacture a
medicinal product for which a marketing authorisation has
been suspended by a competent authority.
Where the new psychoactive substance falls into one of the
categories listed under the first subparagraph, the
Commission, on the basis of data collected by EMCDDA
and Europol, shall assess with the EMEA the need for
further action, in close cooperation with the EMCDDA
and in accordance with the mandate and procedures of
the EMEA.
The Commission shall report to the Council on the
outcome.
Article 8
Procedure for bringing specific new psychoactive
substances under control
1. Within six weeks from the date on which it received the
Risk Assessment Report, the Commission shall present to the
Council an initiative to have the new psychoactive substance
subjected to control measures. If the Commission deems it is
not necessary to present an initiative on submitting the new
psychoactive substance to control measures, within six weeks
from the date on which it received the Risk Assessment Report,
the Commission shall present a report to the Council explaining
its views.
2. Should the Commission deem it not necessary to present
an initiative on submitting the new psychoactive substance to
control measures, such an initiative may be presented to the
Council by one or more Member States, preferably not later
than six weeks from the date on which the Commission
presented its report to the Council.
3. The Council shall decide, by qualified majority and acting
on an initiative presented pursuant to paragraph 1 or 2, on the
basis of Article 34(2) (c) of the Treaty, whether to submit the
new psychoactive substance to control measures.
Article 9
Control measures taken by Member States
1. If the Council decides to submit a new psychoactive
substance to control measures, Member States shall endeavour
to take, as soon as possible, but no later than one year from the
date of that decision, the necessary measures in accordance with
their national law to submit:
(a) the new psychotropic drug to control measures and
criminal penalties as provided under their legislation by
virtue of their obligations under the 1971 United Nations
Convention on Psychotropic Substances;
(b) the new narcotic drug to control measures and criminal
penalties as provided under their legislation by virtue of
their obligations under the 1961 United Nations Single
Convention on Narcotic Drugs.
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2. Member States shall report the measures taken to both the
Council and the Commission as soon as possible after the
relevant decision has been taken. Thereafter this information
shall be communicated to the EMCDDA, Europol, the EMEA,
and the European Parliament.
3. Nothing in this Decision shall prevent a Member State
from maintaining or introducing on its territory any national
control measure it deems appropriate once a new psychoactive
substance has been identified by a Member State.
Article 10
Annual report
The EMCDDA and Europol shall report annually to the
European Parliament, the Council and the Commission on the
implementation of this Decision. The report will take into
account all aspects required for an assessment of the efficacy
and achievements of the system created by this Decision. The
Report shall, in particular, include experience relating to coor-




Member States and the EMEA shall ensure an appropriate
exchange of information between the mechanism set up by
means of this Decision and the pharmacovigilance systems as
defined and established under Title VII of Directive 2001/82/EC
and Title IX of Directive 2001/83/EC.
Article 12
Repeal
The Joint Action on New Synthetic Drugs of 16 June 1997 is
hereby repealed. Decisions taken by the Council based on
Article 5 of that Joint Action shall continue to be legally valid.
Article 13
Publication and taking effect
This Decision shall take effect on the day following that of its
publication in the Official Journal of the European Union.
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Annex 2 — New psychoactive substances reported to the EMCDDA and Europol for the 
first time in 2010 under the terms of Council Decision 2005/387/JHA  
 
 
1. 2C-B-BZP (1-(4-bromo-2,5-dimethoxybenzyl)piperazine) – 18 January 2010 – Germany 
 
2. MDAI (5,6-methylenedioxy-2-aminoindane) – 26 February 2010 – Sweden 
 
3. -Me-PEA (2-phenylpropan-1-amine) – 26 February 2010 – Norway 
 
4. N-benzyl-1-phenethylamine – 26 February 2010 – Norway 
 
5. N,N-dimethylphenethylamine – 26 February 2010 – Norway 
 
6. 4-FMA (4-fluoromethamphetamine) – 24 March 2010 – Norway 
 
7. RCS-4 ((4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone) – 25 May 2010 – Hungary  
 
8. JWH-081 (1-pentyl-3-(4-methoxy-1-naphthoyl)indole) – 2 June 2010 – Latvia  
 
9. Naphyrone (naphthylpyrovalerone) – 11 June 2010 – Sweden  
 
10. Iso-ethcathinone (1-ethylamino-1-phenyl-propan-2-one) – 18 June 2010 – Ireland   
 
11. DMAA (1,3-dimethylamylamine) – 21 June 2010 – Ireland 
 
12. Dimethocaine ((3-diethylamino-2,2-dimethylpropyl)-4-aminobenzoate) – 21 June 2010 – 
Ireland 
 
13. JWH-073 methyl derivative (1-Butyl-3-(1-(4-methyl)naphthoyl)indole)) – 30 June 2010 – 
Germany  
 
14. Buphedrone (2-(methylamino)-1-phenylbutan-1-one) – 5 July 2010 –  Finland 
 
15. 4-methylethcathinone (2-Ethylamino-1-(4-methylphenyl)-1-propanone) – 8 July 2010 – 
United Kingdom 
 
16. AM-694 (1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone) – 19 July 2010 – 
Ireland  
 
17. JWH-122 (1-pentyl-3-(4-methyl-1-naphthoyl)indole) ) – 23 July 2010 – Latvia  
 
18. MPBP (4’-methyl--pyrrolidinobutyrophenone) – 27 July 2010 – Bulgaria  
 
19. JWH-015 (1-propyl-2-methyl-3-(1-naphthoyl)indole) ) – 27 July 2010 – Austria  
 
20. 4-MBC (4-methyl-N-benzylcathinone) – 16 August 2010 – United Kingdom 
 
21. MPPP (4'-Methyl--pyrrolidinopropiophenone) – 16 August 2010 – United Kingdom 
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23. 1-naphthalen-1-yl-2-pyrrolidin-1-yl-pentan-1-one – 18 August  2010 –  United Kingdom  
 
24. Pentylone (2-Methylamino-1-(3,4-methylenedioxyphenyl)pentan-1-one) – 3 September 
2010 – United Kingdom 
 
25. M-ALPHA (1-methylamino-1-(3,4-methylenedioxy-phenyl)propane) – 3 September 2010 – 
United Kingdom 
 
26. 5-MeO-DPT (5-methoxy-N,N-dipropyltryptamine) – 13 September 2010 – Finland  
 
27. -Ethyl-Methcathinone (2-methylamino-1-phenyl-1-pentanone) – 17 September 2010 – 
Austria  
 
28. JWH- 210 (4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone) – 22 September 2010 – 
Germany 
 
29. 3,4-Dimethylmethcathinone (1-(3,4-dimethylphenyl)-2-(methylamino)propan-1-one) – 13 
October 2010 – Hungary  
 
30. JWH-203 (2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone) – 14 October 2010 – Latvia  
 
31. JWH-019 (1-hexyl-3-(1-naphthoyl)indole) – 26 October 2010 – Finland  
 
32. Methoxetamine (2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone) – 9 November 2010 
– United Kingdom  
 
33. 3-(4-Hydroxymethylbenzoyl)-1-pentylindole – 9 November 2010 – United Kingdom  
 
34. MDPBP (3',4'-methylenedioxy--pyrrolidinobutyrophenone) – 17 November 2010 – United 
Kingdom  
 
35. 3-MeO-PCE (3-methoxyeticyclidine) – 17 November 2010 – United Kingdom  
 
36. DiButylone or bk-MMBDB (2-dimethylamino-1-(3,4-methylenedioxyphenyl)-butan-1-one) 
– 18 November 2010 – Finland  
 
37. Arecoline (methyl methyl-1,2,5,6-tetrahydropyridine-3-carboxylate) – 22 November 2010 
– United Kingdom 
 
38. BMDP (2-benzylamino-1-(3,4-methylenedioxyphenyl)propan-1-one) – 9 December 2010 – 
United Kingdom 
 
39. BMDB (2-benzylamino-1-(3,4-methylenedioxyphenyl)butan-1-one) – 9 December 2010 – 
United Kingdom 
 
40. 5-APB (5-(2-aminopropyl)benzofuran) – 14 December 2010 – United Kingdom 
 
41. Desoxy-D2PM (2-(diphenylmethyl)pyrrolidine) – 23 December 2010 – United Kingdom 
 
 
 
